Long-term registry following people with psoriasis on systemic treatments
Follows adults with psoriasis over 10 years on systemic treatments, including biologics.
Plain-language title generated from the registry record
Registry title: Swiss Dermatology Network of Targeted Therapies (SDNTT)
Key facts
- Where
- Aarau, Basel, Bern, Lausanne, Sankt Gallen, and Zurich, SwitzerlandSee the 6 sites
Where in Switzerland
- Aarau Cantonal HospitalAarau, SwitzerlandTaking people
- Basel University HospitalBasel, SwitzerlandTaking people
- Inselspital, Bern University HospitalBern, SwitzerlandTaking people
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandTaking people
- St. Gallen Cantonal HospitalSankt Gallen, SwitzerlandTaking people
- Zurich University HospitalZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Swiss Dermatology Network for Targeted Therapies
- Trial code
- NCT01706692
- Record updated
- 29 November 2024
- Original description
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.Read full original descriptionShow less
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.
The registry will also evaluate safety clinical outcomes and health related quality of life.
Inclusion: Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,; age ≥ 18,; Being administered a specific biologic/conventional systemic drug for the first time; Sufficient language skills (German, French, Italian and English) for the informed consent to participate; Informed consent to participate.
Exclusion: Lack of informed consent; Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately).